

September 15, 2017

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Christine Westbrook

**Re: Krystal Biotech, Inc.**  
**Registration Statement on Form S-1**  
**File No. 333-220085**

**Acceleration Request**

**Requested Date: Tuesday, September 19, 2017**  
**Requested Time: 4:30 p.m., Eastern Daylight Time**

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Ladenburg Thalmann & Co. Inc. hereby joins Krystal Biotech, Inc. in requesting that the Securities and Exchange Commission (the "**Commission**") take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-220085) to become effective on September 19, 2017, at 4:30 p.m., Eastern Daylight Time, or as soon as practicable thereafter.

Additionally, pursuant to Rule 460 of the Act, we hereby advise you that approximately 300 copies of the Preliminary Prospectus, dated September 7, 2017, were distributed by us from September 11, 2017 through the date hereof to underwriters, institutions, dealers and others.

We will comply, and have been informed by the participating underwriters that they will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

---

Very truly yours,

**Ladenburg Thalmann & Co. Inc.**

By: /s/ David J. Strupp, Jr.

Name: David J. Strupp, Jr.

Title: Managing Director

cc: Michael Maline, Goodwin Procter LLP  
John W. Campbell III, Morrison & Foerster LLP